Prelude Therapeutics Advances Oncology Pipeline with Key Clinical Milestones and Lilly Collaboration
Event summary
- Prelude Therapeutics initiated Phase 1 study of PRT13722, a KAT6A degrader for HR+ breast cancer, with initial proof-of-concept data expected in 2H 2027.
- Entered clinical trial collaboration with Lilly to evaluate PRT13722 in combination with Verzenio® and Inluriyo® in HR+/HER2- breast cancer.
- Continued enrollment in Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis.
- Preclinical data from mCALR-targeted degrader antibody conjugate accepted for presentation at ASH 68th Annual Meeting in December 2026.
- Reported $142.7 million in cash and cash equivalents as of September 30, 2026, with runway into 2Q 2028.
The big picture
Prelude Therapeutics is positioning itself as a key player in precision oncology, leveraging targeted protein degradation technology to develop innovative treatments for high-unmet-need indications. The company's strategic collaborations, particularly with Lilly, underscore the potential of its pipeline to deliver transformative therapies. With multiple clinical readouts on the horizon, Prelude is poised to drive future growth through its differentiated approach to clinically validated targets.
What we're watching
- Clinical Progress
- The pace at which PRT13722 and PRT12396 advance through clinical trials will determine Prelude's ability to secure future partnerships or licensing deals.
- Strategic Partnerships
- The collaboration with Lilly on PRT13722 could enhance the drug's development trajectory and commercial potential.
- Financial Sustainability
- Whether Prelude's current cash runway will be sufficient to support operations until potential revenue-generating milestones are achieved.
Related topics
